



Att. Docket No.: REG 930A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Radziejewski and Shi

Serial No.: 10/699,361

Group: Not Yet Assigned


Filing Date: October 31, 2003

Examiner: Not Yet Assigned

Title: Modification Assisted Profiling (MAP) Methodology

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: MS Information Disclosure Statement, Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450..


Loren Hernandez

4/10/04
Date

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
US Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

- ☐ (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

☒ (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☒ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

☐ (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;


and

☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

Fees

No fee is required for the filing of this Information Disclosure Statement. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted

A handwritten signature in cursive script, reading "Valeta Gregg", is written over a horizontal line.

Valeta Gregg
Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



FORM PTO-1449

Att. Docket No. REG 930A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 930A
Serial No. : 10/699,361
Applicant: : Czeslaw Radziejewski and Ergang Shi
Date Filed : October 31, 2003
For : Modification Assisted Profiling (MAP)
Methodology
Examiner : Not Yet Known
Group Art Unit : Not Yet Known

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	_____	_____	_____	_____	_____

OTHER DOCUMENTS

Examiner
Initials

_____ Steinrücke, P., et al., 2000, "Design of Helical Proteins for Real-time
Endoprotease Assays", Anal. Biochem. 286:26-34.

_____ Haggarty, S., et al., 2003, "Chemical Genomic Profiling of Biological
Networks Using Graph Theory and Combinations of Small
Molecule Perturbations", J. Am. Chem. Soc. 125:10543-10545.

EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in
conformance with MPEP 609; draw line through citation if
not in conformance and not considered. Include copy of this
form with next communication to applicant.

Respectfully submitted,

By: Valeta Gregg
Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400